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Abstract
Objectives: Using the Wilson and Cleary model linking clinical variables to quality of life, we explored the associations
between physical and psychological factors, disability, perceived health and quality of life in ALS/MND. Methods: The
ongoing UK study of Trajectories of Outcomes in Neurological Conditions (TONiC) recruited participants with ALS/
MND to complete a questionnaire pack including demographic factors and several patient reported outcome measures
(PROMs); a clinician provided data on disease onset type and duration since diagnosis. All PROMs were transformed
from ordinal raw scores to interval-scaled latent estimates via the Rasch measurement model. Results: Data from 636
patients were analyzed; mean age 65.1 years (SD 10.7), 61.3% male. Median duration since diagnosis was 11.2 months
(IQR 4.6–29.9; range 0.4–295.9 months); 67.3% had limb and 27.3% bulbar onset disease. Symptoms such as breath-
lessness and fatigue, along with most domains of activity limitations, were shown to vary by onset type. A series of mod-
els illustrated the importance of physical functioning and anxiety upon quality of life, with breathlessness and fatigue
having indirect effects. The models were invariant for gender and onset type. Conclusions: This large study highlights the
importance of functional status and anxiety as key variables influencing quality of life in ALS/MND. The nature and
diversity of factors, both physical and psychological, which have been shown to influence the quality of life of people
with ALS/MND provide strong evidence in support of the widespread implementation of multidisciplinary care.
Keywords: Amyotrophic lateral sclerosis, Wilson and Cleary model, TONiC; quality of life, multidisciplinary care
Introduction
Amyotrophic lateral sclerosis/motor neuron disease
(ALS/MND) is a progressive, adult-onset, neuro-
degenerative disease which causes profound phys-
ical disability, including paralysis, loss of verbal
communication, and inability to swallow; death is
usually related to respiratory failure. Treatments
are palliative and interventions may extend life
without stopping disease progression. Faced with
this bleak prognosis, prevalence rates for depres-
sion in ALS/MND patients are up to 44% and for
anxiety up to 30% (1), worsening as the disease
progresses (2).
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Given our current inability to cure ALS/MND
or to halt its progression, the focus of care is the
optimization of the patient’s quality of life. Health-
related quality of life in ALS/MND can be severely
compromised; on an EQ-5D derived single index
score where full health is 1 and values lower than
0 represent states considered to be worse than
death (3), patients scored a mean of 0.63 for initial
stage 1 disease severity to a mean of –0.01 for
more disabled stage 4 disease severity (2,4).
Quality of life in ALS/MND is influenced by a var-
iety of psychological as well as physical factors
(5,6), and the clinical challenge is to understand
how to intervene regarding the complex interplay
of these physical and psychological factors.
Conceptual models can help us clarify such rela-
tionships, enhancing our understanding of the net-
work of factors and the effects of mediators and
moderators, thereby potentially improving clin-
ical care.
One such model was proposed by Wilson and
Cleary (7,8). This model proposes a causal path-
way beginning with “physiological and biological”
factors, which influence symptoms. Symptoms are
defined as a patient’s perception of an abnormal
physical, emotional, or cognitive state, and these in
turn may affect functioning. Following from these
are health perceptions, a subjective rating which
integrates the previous three health concepts of
biology, symptoms, and functioning, along with
others such as personal and environmental situ-
ation. At the end of the continuum is quality of
life (8) (see Figure 1). The authors hoped that “a
clear understanding of these causal relationships
will facilitate the design of optimally effective clin-
ical interventions” (8). While the model has been
validated in several chronic conditions, it has never
before been studied in ALS/MND (9). The cur-
rent study uses the Wilson and Cleary model to
explore the associations between onset type, phys-
ical and psychological factors, perceived health and
quality of life in a large cohort of people with
ALS/MND, who are part of the ongoing UK lon-
gitudinal study of Trajectories of Outcomes in




The TONiC study recruited participants with
ALS/MND across many UK centers, asking them
to complete a questionnaire pack including demo-
graphic factors and a variety of patient reported
outcome measures (PROMs). As well as quality of
life, these PROMs assessed factors deemed import-
ant for quality of life in earlier qualitative work
conducted with a range of people with ALS/MND
(10,11). In addition, a clinician provided data on
disease onset type and duration since diagnosis.
All participants received written information and
informed consent was obtained prior to enrollment
into the study. Ethical approval was granted from
the relevant local research committees (reference
11/NW/0743).
Outcome measures included in current analysis
1. Neurological Fatigue Index-MND (NFI-
MND) (12)—13 items generating weakness,
energy and summary scales, each capable of
interval level measurement. Summary scale
used in path models.
2. Dyspnoea-12 (13)—12 items measuring
severity of breathlessness, incorporating
physical and affective aspects.
3. Hospital Anxiety and Depression Scale adapted
for MND (HADS-MND) (14,15)—one item
from each of anxiety and depression scales
required removal due to misfit on the Rasch
analysis and cutoff points for probable
depression and anxiety were revised to account
for the reduced number of items.
Figure 1. The Wilson and Cleary conceptual model of health-related quality of life.
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4. Amyotrophic Lateral Sclerosis Functional
Rating Scale-Revised (ALSFRS-R) (16,17)—
12 items providing estimates of disability in
bulbar (three items), motor (six items), and
respiratory (three items) domains.
5. World Health Organization’s Disability
Assessment Schedule-2.0 (WHODAS-2.0)
(18)—seven domains covering: Understanding
and Communicating (six items), Getting
around (five items), Self-care (four items),
Getting along with others (five items), Life
activities: household (four items), and
Participation in society (eight items), total
score without the four work-related items used
in path models.
6. Numeric rating scales (NRSs) for perceived
health and quality of life—where a high score
is better.
7. World Health Organization Quality of Life
Scale-BREF (WHOQOL-BREF) (19)—26
items, covering four domains: physical,
psychological, social and environment, and two
summary items. Ten items are prefaced with
“How satisfied are you… ?” and provide a “life
satisfaction” operationalization of quality of life
for use in the path models.
Rasch analyses
These variables were intended to provide a rele-
vant disease-specific interpretation of the Wilson
and Cleary model of health related quality of life,
as outlined in Figure 1 (8). The ordinal scores
from all PROMs were first transformed to interval-
scaled latent estimates via fit of their data to the
Rasch measurement model (20,21). The iterative
process of the Rasch analysis is designed to verify
the underlying assumptions of stochastic ordering
of items; local independence, including response
and trait dependence, and group invariance (e.g.
for age or gender) (22–24). Full details of this pro-
cess are given elsewhere (25,26). Where the
assumption of local response dependence is
breached, “testlets” or “super items” are formed
by adding the dependent items together (27).
Given two testlets absorbing all items, a latent esti-
mate based upon a bi-factor equivalent solution
with a conditional test of fit becomes available
(28). The explained common variance (ECV) is
reported where a value of 1 indicates that all non-
error variance is contained within the latent esti-
mate. An ECV value >0.9 is considered sufficient
to indicate that the first common factor is unidi-
mensional (29). Values above 1 can be obtained,
indicating that some local dependency remains
across the two testlets.
Path models
Given fit of data to the Rasch model, the resulting
interval-scaled estimates become available to be
entered into a path model, together with the dir-
ectly observed variable of age, an NRS of per-
ceived health; disease onset type, gender, and
disease duration were used as grouping variables
(moderators) (30). Comparison of onset type is
restricted to bulbar versus limb onset, due to low
numbers in the unknown and respiratory groups.
Each model is tested by a Wald statistic for invari-
ance by gender, disease duration, and onset type,
to examine whether the same model holds irre-
spective of group membership. Given the sample
size, indication that the data provide an accurate
representation of the model is indicated by a non-
significant chi-square statistic (31).
The focal relationship in the initial model is
between symptoms and quality of life, and all
other variables are defined in this context (32,33).
The initial model hypothesizes that the effects of
breathlessness and fatigue (symptoms) upon per-
ceived health are fully mediated by functional sta-
tus (summarized by the WHODAS-2.0); that is
their effect passes fully through functional status
rather than directly (or both ways) to perceived
health. Likewise, the impact of functional status
upon quality of life is fully mediated by per-
ceived health.
Subsequent analyses explore the role of anxiety
to test how it contributes to the overall under-
standing of the lived experience of those with ALS/
MND in the context of impact upon their quality
of life. Anxiety in ALS/MND may be considered a
consequence of the increasing levels of symptoms
and activity limitations, and in turn anxiety may
affect perceived health and quality of life.
The same underlying concept can be measured
by different PROMs, such as measuring functional
status by the WHODAS-2.0 or ALSFRS-R. The
final model is re-specified to be based upon the
ALSFRS-R, to show how different PROMs can be
used to operationalize the Wilson and
Cleary model.
The descriptive analysis was undertaken in
SPSS24 (SPSS Inc., Chicago, IL), the path ana-
lysis in STATA15 (StataCorp LLC, College
Station, TX), and the Rasch analysis in
RUMM2030 (Perth, Australia) (34–36).
Results
Patients and descriptive characteristics of domains
This analysis used data from the first 636 patients
with ALS/MND to join the study and return the
baseline questionnaire. Mean age was 65.1 years
(SD 10.7), 61.3% were male, and median duration
since diagnosis was 11.2 months (IQR 4.6–29.9;
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range 0.4–295.9 months). According to onset type,
428 (67.3%) had limb onset, 174 (27.4%) had
bulbar onset, and 11 (1.7%) were recorded as hav-
ing a respiratory onset; 23 (3.6%) had unknown
onset. Disease duration differed between people
with bulbar and limb onset, with those with bulbar
onset having the shortest average duration at 20.1
months compared with limb onset at 28.5 months
(t¼2.837; p¼ 0.005). Most were married
(78.6%), and were able to complete the question-
naire independently (61%). Just 12.9% were
employed, either full time or part time.
The median and inter-quartile ranges for each
onset type and in total, for all the above scales
where reporting takes the form of ordinal scores,
along with mean values for age and duration, are
given in Table 1. The bulbar, motor, and respira-
tory domains of the ALSFRS-R all showed a sig-
nificant difference mostly consistent with onset
type; bulbar onset having the lowest rank (worst)
for the ALSFRS-R bulbar domain, and respiratory
onset for the ALSFRS-R respiratory domain (all
domains Kruskal–Wallis p0.001) (Table 1). The
Dyspnoea-12 showed strong discrimination





appropriate testBulbar Limb Respiratory
Demographics
Age 16–90 years 67.0 [10.2] 64.2 [10.8] 67.5 [6.8] 65.0 [10.7] 0.011
Duration 0–296 months 20.1 [28.9] 28.5 [41.3] 24.2 [31.0] 26.0 [38.1] 0.049
PROMs
ALSFRS-R
Bulbar 0–12 5 [2–7] 11 [9–12] 12 [10–12] 9 [6–12] <0.001
Motor 0–24 17 [12–21] 14 [10–17] 11 [6–20] 14 [10–18] <0.001
Respiratory 0–12 10 [8–12] 11 [9–12] 4 [3–10] 11 [9–12] <0.001
Dyspnoea-12
Total 0–36 5 [0–12] 2 [0–9] 13 [7–15] 3 [0–11] <0.001
Physical 0–21 3 [0–9] 0 [2–7] 10 [5–14] 3 [0–8] <0.001
Affective 0–15 0 [0–1] 0 [0–0] 1 [0–5] 0 [0–2] <0.001
HADS-MND
Anxiety 0–18 5 [2–7] 4 [2–7] 3 [1–7] 4 [2–7] 0.319
Depression 0–18 3 [1–5] 3 [1–6] 4 [3–7] 3 [1–5] 0.209
NFI-MND
Weakness 0–21 12]8–14] 13 [10–16] 16 [10–18] 13 [10–16] 0.001
Energy 0–21 10 [7–13] 11 [8–13] 11 [6–13] 11 [8–13] 0.375
Summary 0–24 13 [9–16] 14 [11–17] 15 [9–19] 14 [11–17] 0.009
WHODAS-2.0 (32 items excluding work)
Communication 0–24 3 [1–6] 1 [0–4] 1 [0–1] 1 [0–4] <0.001
Mobility 0–20 9 [2–14] 12 [7–16] 16 [8–17] 12 [6–16] 0.001
Self care 0–16 5 [2–8] 7 [3–12] 10 [1–14] 7 [3–11] <0.001
Getting along 0–20 5 [2–8] 3 [1–5] 4 [4–4] 4 [1–6] <0.001
Life activities 0–16 8 [2–12] 11 [6–16] 16 [12–16] 10 [5–15] <0.001
Participation 0–32 9 [6–14] 10 [6–14] 13 [8–17] 6 [10–14] 0.402
Summary (32) 0–128 40 [21–62] 48 [31–64] 67 [45–69] 46 [27–64] 0.016
WHOQoL—Bref
Physical 7–35 23 [20–28] 22 [19–25] 20 [18–27] 22 [19–26] 0.009
Psychological 6–30 23 [19–25] 22 [19–24] 23 [17–26] 22 [19–25] 0.818
Social 3–15 12 [10–13] 12 [10–13] 11 [10–12] 12 [10–13] 0.468
Environmental 8–40 32 [30–35] 30 [28–33] 31 [30–36] 31 [28–34] <0.001
Life satisfaction 10–50 37 [32–41] 35 [31–39] 36 [32–38] 35 [31–40] 0.012
Numeric rating scales
Perceived health 0–10 6 [4–8] 5 [4–7] 7 [4–8] 6 [4–7] 0.250
QoL 0–10 7 [5–8] 6 [5–8] 6 [5–8] 6 [5–8] 0.535
N – 174 429 11 614 –
PROMs: patient reported outcome measures; ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; HADs-
MND: Hospital Anxiety and Depression Scale adapted for MND; NFI-MND: Neurological Fatigue Index-MND; WHODAS-2.0:
World Health Organization’s Disability Assessment Schedule-2.0; WHOQoL-Bref: World Health Organization Quality of Life
Scale-Bref.
Mean and [SD] for age and duration, median, and [inter-quartile range] for PROMs. High score is good; 22 cases omitted where
onset type is unknown.
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between respiratory onset, and other types, while
both the Weakness and Summary domains of the
NFI-MND showed a significant difference across
onset type (Kruskal–Wallis p0.01), but not the
Energy domain. The Communication, Self-care,
Mobility, Getting Along with People and Life
Activities domains of the WHODAS-2.0 differed
by onset type (Kruskal–Wallis p0.001), whereas
the Participation domain showed no such differ-
ence. The total score of the WHODAS-2.0 (minus
the four work items) also differed by onset type.
Overall, from the HADS-MND, 11.1% had
“probable” depression, and 13.8% “probable”
anxiety. Neither differed by onset type (chi-square
p0.05), and nor did their ordinal scores. Despite
the observed differences across onset type for
many PROMs, perceived health, as represented by
an NRS, did not show any difference by onset
type (Kruskal–Wallis p¼ 0.250). Finally, while the
Physical, Environmental, and Life Satisfaction
domains of the WHOQOL-BREF differed by
onset type, the Psychological domain and Social
domain did not (Kruskal–Wallis p0.05), and
neither did the summary NRS item for quality of
life (Kruskal–Wallis p 0.05). Using the inter-
quartile range to define duration groups, one-quar-
ter of the sample had a duration of 4.6 months or
less, and overall an expected increasing gradient
was observed for the WHODAS-2.0 across dur-
ation groups (Kruskal–Wallis p¼ 0.0001). Within
the WHODAS-2.0, the Life Activities domain
showed an increase in limitations as duration
increased (Kruskal–Wallis p¼ 0.00001), and the
Participation domain also showed an increase in
restriction (Kruskal–Wallis p¼ 0.001).
Rasch analysis
Fit of the data from the various PROMs is shown
in Table 2. After adjusting for local response
dependency where necessary, all PROMs showed
fit to the Rasch model with the exception of the
ALSFRS-R respiratory domain and the
WHOQOL-BREF Social domain, both of which
also showed low reliability. The 10 “life sat-
isfaction” items from the WHOQOL-BREF met
all the requirements of the Rasch model.
Table 2. Fit of scales to the Rasch model.
Conditional chi-square fit Reliability
ECV
Value df p PSI a % common variance
Ideal values >0.05 >0.7 >0.7 >0.90
PROMs
ALSFRS-R
Bulbar 4.27 4 0.371 0.67 0.81 1.03
Motor 29.11 16 0.023 0.85 0.84 1.05
Respiratory 19.56 4 <0.001 0.37 0.58 0.96
Dyspnoea-12
Total 28.18 23 0.209 0.85 0.98 1.07
Physical 26.59 12 0.009 0.85 0.95 1.07
Affective 3.32 7 0.854 0.65 0.92 1.39
HADS-MND
Anxiety 13.96 10 0.175 0.77 0.84 0.99
Depression 10.92 7 0.142 0.67 0.74 1.01
NFI-MND
Weakness 18.51 13 0.139 0.85 0.89 1.03
Energy 19.08 10 0.039 0.87 0.92 1.03
Summary 13.86 16 0.609 0.87 0.89 1.00
WHODAS-2.0 (32 items excluding work)
Summary 100.02 92 0.266 0.94 0.97 1.03
WHOQOL—BREF
Physical 20.36 19 0.373 0.80 0.79 1.01
Psychological 19.49 14 0.147 0.79 0.77 0.93
Social 9.14 3 0.027 0.57 0.45 0.65
Environmental 25.9 18 0.102 0.77 0.76 0.93
Life satisfaction 30.3 25 0.214 0.81 0.81 1.01
Ideal values – – >0.05 >0.7 >0.7 >0.9
PROMs: patient reported outcome measures; ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; HADs-
MND: Hospital Anxiety and Depression Scale adapted for MND; NFI-MND: Neurological Fatigue Index-MND; WHODAS-2.0:
World Health Organization’s Disability Assessment Schedule-2.0; WHOQOL-BREF: World Health Organization Quality of Life
Scale-BREF; PSI: Person Separation Index; ECV: explained common variance; a: Cronbach’s alpha.
Embolden and italicized values indicative of misfit.
Bonferroni’s correction p¼0.003.
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Path analysis
A hypothesized representation of the Wilson and
Cleary model was tested, using the various
PROMs listed above (Figure 2). The initial model
hypothesizes that the effects of breathlessness and
fatigue (symptoms) upon perceived health are fully
mediated by functional status (summarized by the
WHODAS-2.0) and the impact of functional sta-
tus upon quality of life is fully mediated by per-
ceived health. The initial model, essentially a
linear representation of effects, is not supported by
the observed data. The model as a whole, while all
paths are significant, did not satisfy the chi-square
goodness of fit test (chi-square 70.3; p< 0.001).
The principal problem was mis-specification, in
that the modification indices showed that fatigue
should have a direct effect on perceived health,
making its impact partially mediated, and func-
tional status should have a direct effect on quality
of life, thus partially mediated by perceived health.
Adjusting for this, the data become an accurate
representation of the hypothesized model (chi-
square 2.37; df 3; p¼ 0.499) (Figure 3).
Furthermore, the model is invariant for gender,
Figure 2. Initial representation of an ALS/MND Wilson and Cleary model. Standardized estimates. NFI-MND-Summ: Neurological
Fatigue Index-MND-summary scale; WHODAS: World Health Organization Disability Assessment Schedule–2.0; WHOQOL-Bref:
World Health Organization Quality of Life Scale-BREF.
Figure 3. ALS/MND and the Wilson and Cleary Model. Standardized estimates. NFI-MND-Summ: Neurological Fatigue Index-
MND-summary scale; WHODAS: World Health Organization Disability Assessment Schedule–2.0; WHOQOL-Bref: World Health
Organization Quality of Life Scale-BREF.
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duration and onset type (Wald’s test >0.05).
Overall, the model for quality of life had R2 0.53.
Including onset type as a moderator (interaction
term) into the model resulted in an adjusted R2 for
quality of life ranging from 0.44 for limb onset,
through 0.49 for bulbar onset, to 0.58 for respira-
tory onset. In this model, impaired functional status
(activity limitations) is the main contributor to a
poorer quality of life (Table 3). Perceived health is
next, and both fatigue and breathlessness contribute
“behind the scenes” through indirect effects.
Anxiety may be considered a consequence of
the increasing levels of symptoms and activity limi-
tations, and in turn may affect perceived health
and quality of life (Figure 4). In this model, the
focal relationship remains between symptoms and
quality of life. The data provided an accurate rep-
resentation of the model (chi-square 3.48; df 4;
p¼ 0.480). The model R2 for quality of life was
0.57. Once again activity limitations played the
major role in influencing quality of life but in this
model, anxiety had the second greatest influence
Table 3. Standardized direct, indirect and total effects upon quality of life.
Model
Effect
Total Chi-square model fitVariable Scale Direct Indirect
Figure 3 ! QoL p¼0.499
Function WHODAS-2.0 –0.623 –0.081 –0.704
Perceived health NRS 0.192 – 0.192
Fatigue NFI-MND – –0.169 –0.169
Breathlessness Dyspnoea-12 – –0.060 –0.060
Figure 4 ! QoL p¼0.480
Function WHODAS-2.0 –0.549 –0.154 –0.703
Anxiety HADS-MND-A –0.221 –0.018 –0.239
Perceived health NRS 0.167 – 0.167
Fatigue NFI-MND – –0.167 –0.167
Breathlessness Dyspnoea-12 – –0.082 –0.082
Figure 5 ! QoL p¼0.603
Motor ALSFRS-Motor 0.442 0.061 0.503
Respiratory ALSFRS-Respiratory – 0.409 0.409
Anxiety HADS-MND-A –0.349 –0.038 –0.387
Perceived health NRS 0.215 – 0.215
Bulbar ALSFRS-Bulbar – –0.075 –0.075
QoL: quality of life; NRS: numeric rating scale; ALSFRS: Amyotrophic Lateral Sclerosis Functional Rating Scale-
Revised; HADs-MND-A: Anxiety domain from Hospital Anxiety and Depression Scale adapted for MND; NFI-
MND: Neurological Fatigue Index-MND; WHODAS-2.0: World Health Organization’s Disability Assessment
Schedule-2.0.
Figure 4. Anxiety as consequent to symptoms and functional status, and its effect upon perceived health and quality of life.
Standardized estimates. NFI-MND-Summ: Neurological Fatigue Index-MND-summary scale; WHODAS: World Health Organization
Disability Assessment Schedule–2.0; WHOQOL-Bref: World Health Organization Quality of Life Scale-BREF; HADS_A: Hospital
Anxiety and Depression Scale adapted for MND-anxiety subscale.
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(Table 3). The model was invariant for gender,
duration and onset type (constrained to limb
and bulbar).
Figure 5 shows the model as specified through
ALSFRS-R domains. The data adequately repre-
sent the model (chi-square 2.20; df 5; p¼0.821).
Once again activity limitations dominate, along
with ALSFRS-Motor, with anxiety following in
influence. The model R2 for quality of life was
0.52. Unlike the model using WHODAS-2.0, this
model with ALSFRS-R was not invariant for gen-
der, duration, and onset type. There was some dif-
ference in path parameters between bulbar and
limb by gender, and by duration, but these differ-
ences appeared to be one of magnitude as the par-
ameter remained significant across groups
(Wald’s test).
Discussion
This baseline dataset from the TONiC study illus-
trates the pathways between physical symptoms,
and psychological symptoms, through functional
status, to perceived health and quality of life, as
experienced by people with ALS/MND. We
showed that onset type and duration of condition
had the greatest influence on breathlessness,
fatigue in terms of NFI-MND weakness or sum-
mary score, disability as measured by ALSFRS-R,
most domains of WHODAS-2.0, and the physical,
environmental, and life satisfaction domains of the
WHOQOL-BREF. For example, bulbar onset
patients had shorter duration with worse symptoms
and physical functioning. An earlier smaller study
reported that bulbar onset is related to a worse
outcome, along with age of onset (37). Another
earlier smaller study reported that bulbar com-
pared to limb onset is an important factor in qual-
ity of life changes during the disease course (38).
In the current study, anxiety, depression, perceived
health and psychological and social quality of life
showed no differences across onset type.
The chosen set of PROMs showed adequate fit
to the Rasch model, so enabling the Wilson and
Cleary model to be operationalized by linear trans-
formed values of the PROMs raw scores in the
form of a path analysis. These estimates are
entered into the model as single indicator latent
variables, with their error and regression weights
pre-defined. From a conceptual perspective, after
some adjustment, the empirical data was shown to
provide a good representation of the model, imply-
ing a mostly linear trajectory from symptoms
through functional status to perceived health and
quality of life. A recent review showed that the
Wilson and Cleary model was a robust conceptual
framework to characterize predictors of quality of
life in 26 studies across 13 conditions; however,
the single study examining stroke means we cur-
rently have little data on the validity of the model
in neurological conditions (9).
The symptom status (body functions) and
functional status (activities) in the Wilson and
Cleary model, together with the characteristics of
the individual and the environment, foreshadowed
the International Classification of Functioning,
Disability and Health (ICF) model from the
World Health Organisation (WHO), which was
Figure 5. ALS/MND and the Wilson and Cleary Model as specified through ALSFRS-R domains, showing relation with perceived
health, anxiety and quality of life. Standardized estimates. ALSFRS-Bulbar: Amyotrophic Lateral Sclerosis Functional Rating Scale-
Revised-Bulbar subscale; ALSFRS_Resp: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised –respiratory subscale;
ALSFRS-Limb: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised-motor subscale; MHADS-A: Hospital Anxiety and
Depression Scale adapted for MND-anxiety subscale; WHOQOL-Bref: World Health Organization Quality of Life Scale-BREF.
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published some six years later (39). The Wilson
and Cleary model is more comprehensive in that it
extends the later WHO ICF model to include the
antecedents of biological and physiological varia-
bles, and the consequent variables of perceived
health and quality of life. The linearity of the
model, oft criticized in the original WHO ICF
model, is nevertheless largely supported in the cur-
rent study, as well as recent work on the ICF
model itself (40). As such, the Wilson and Cleary
model provides a general framework to explore the
relationships between symptoms (impairments),
functional status (activity limitations), and quality
of life. These relationships can be operationalized
by different PROM instruments, and recent advan-
ces in scale co-calibration provide the ability to
exchange domain-specific scores from different
instruments, so facilitating better comparability
across model-related findings (41). In the current
study, the alternate models utilizing different
PROMs to represent the same domains both gave
similar results in that functional status and anxiety
were dominant in influencing quality of life.
There are limitations to the current study.
Onset type was not available for 23 patients;
although, these were modeled explicitly. The cur-
rent analysis is made upon the baseline data from
a longitudinal study, and as such is cross-sectional
and can only build the case to infer causality.
Nevertheless, the robustness of the path estimates,
including their invariance across groups, suggests
that the results offer a good foundation for further
work to explore these relationships over time.
Subsequent measurement by the TONiC longitu-
dinal study will seek to verify the models as the
disease progresses within individuals, identify
potential different trajectories, and strengthen the
inferences of causality.
The study also has a number of strengths. The
sample size is substantial in ALS/MND research,
making the Rasch analysis of the PROMs robust,
and so too the path analysis and group compari-
sons (42). The PROMs in the TONiC study pro-
vide an unusually comprehensive profile of the
bio-psychosocial experience of the participants.
The TONiC study offers a unique opportunity
to explore the lived experience of those with ALS/
MND from a quantitative perspective, revealing
potential areas for clinical intervention. The model
confirms the importance of multidisciplinary care
in maintaining quality of life for those with ALS/
MND, as the results presented above show the
importance of ameliorating disability, monitoring
symptoms and managing anxiety. Multidisciplinary
teams must optimize functional status through
recurrent interventions, provided in the context of
a declining, progressive condition. Symptoms such
as breathlessness and fatigue are causative for
changes in quality of life and need active clinical
management. Managing anxiety may maintain
quality of life, so teams need psychology input.
Anxiety had strong impact on quality of life, in all
onset types, and played a role even when patients
did not reach thresholds for possible or probable
caseness. The effect of anxiety on quality of life
was evident at all durations of the illness, underlin-
ing that access to psychology cannot be restricted
to the early stage after diagnosis.
In conclusion, the Wilson and Cleary model
has been shown to offer a useful platform for
understanding the lived experience of those with
ALS/MND from a quantitative perspective. It
demonstrates the influence of symptoms and func-
tioning upon perceived health and quality of life,
and highlights the importance of anxiety and func-
tional status as key variables influencing quality of
life in ALS/MND.
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